scorecardresearch
Friday, March 29, 2024
TopicAstraZeneca

Topic: AstraZeneca

Drug regulator sends notice to Serum Institute over AstraZeneca vaccine trial

DCGI issued a show-cause notice to Serum Institute following reports that human trials of the Oxford vaccine were paused in UK after a candidate had an adverse reaction.

AstraZeneca vaccine setback is a reality check in the race to find protection from Covid

In a world crippled by Covid, the AstraZeneca vaccine setback comes as reminder that vaccines can fail or can sometimes deliver more harm than good.

Oxford Covid vaccine trial paused after unexplained illness, AstraZeneca says it’s ‘routine’

Suspension of the trial is a routine action whenever there is a potentially unexplained illness to ensure we maintain integrity of trials, AstraZeneca says.

Oxford vaccine human trial in India a step closer as panel clears Serum Institute protocol 

The protocol will now be moved to DCGI V.G. Somani, who is likely to take a ‘decision by the end of the week’ given the urgency of the Covid challenge.

5 sites in India ready for final phase of human trials of Oxford-AstraZeneca Covid vaccine

The Serum Institute of India will start manufacturing the vaccine even before the final nod so it is ready with sizeable volumes once the vaccine gets all permissions.

India to give 60 of 140 patients for clinical trial of cancer drug Acalabrutinib for Covid

The drug, branded as Calquence by AstraZeneca, has improved clinical outcomes of patients with severe Covid-19, according to a peer-reviewed study.

AstraZeneca-Gilead deal might not actually happen, say analysts

Political opposition from both Britain and America could derail any attempt at a deal, especially given the backdrop of the Covid-19 outbreak.

Why AstraZeneca is pondering a $240 billion gamble with Gilead

Combining the science teams of two pharma giants ought to aid future drug discovery. But it's still not clear if either side needs this deal.

Big pharma is looking beyond coronavirus with AstraZeneca eyeing merger with Gilead

The suggestion of a blockbuster merger between the two drugmakers is a sign that the industry is getting back to something resembling business as usual.

AstraZeneca’s cancer drug shows early signs of promise in treating severe Covid cases

The results, published in Science Immunology, are promising enough for AstraZeneca to launch the second phase of the trial, which will involve 200 patients.

On Camera

India is going to have its least free & fair election in 2024. See these 5 indicators

So far what we have seen of the 2024 elections is enough to indicate that the continuous slide of democratic standards is headed toward breaching the minimum threshold of an electoral democracy.

Congress attacks chief economic advisor over statement on unemployment, asks BJP govt to ‘vacate seat’

While releasing 'India Employment Report 2024', V Anantha Nageswaran said govt can't solve 'all social, economic challenges'. Congress leader Kharge says CEA protecting 'dear leader'.

Amid plans to lift AFSPA, Army starts joint training with Jammu & Kashmir Police

In an interview with Gulistan News this week, Union Home Minister Amit Shah said the government would leave law and order to J&K Police and slowly withdraw troops.

For BJP, Kejriwal is an idea whose time has come to be destroyed

The ‘idea’ Kejriwal's politics grew around was a no-holds-barred fight against corruption. That is the reason Modi govt has now tarred him and his entire party with the same paint.